Isavuconazole + Repaglinide + Caffeine
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pharmacokinetics of Repaglinide
Conditions
Pharmacokinetics of Repaglinide, Pharmacokinetics of Caffeine, Healthy Subjects
Trial Timeline
Jan 1, 2014 → Feb 1, 2014
NCT ID
NCT02128321About Isavuconazole + Repaglinide + Caffeine
Isavuconazole + Repaglinide + Caffeine is a phase 1 stage product being developed by Astellas Pharma for Pharmacokinetics of Repaglinide. The current trial status is completed. This product is registered under clinical trial identifier NCT02128321. Target conditions include Pharmacokinetics of Repaglinide, Pharmacokinetics of Caffeine, Healthy Subjects.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02128321 | Phase 1 | Completed |
Competing Products
20 competing products in Pharmacokinetics of Repaglinide